Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence
IntroductionCurrent evidence shows that serum miR-371a-3p can identify disease recurrence in testicular germ cell tumour (TGCT) patients and correlates with tumour load. Despite convincing evidence showing the advantages of including miR-371a-3p testing to complement and overcome the classical serum...
Main Authors: | Ailsa J. Christiansen, João Lobo, Christian D. Fankhauser, Christian Rothermundt, Richard Cathomas, Aashil A. Batavia, Josias B. Grogg, Arnoud J. Templeton, Anita Hirschi-Blickenstorfer, Anja Lorch, Silke Gillessen, Holger Moch, Jörg Beyer, Thomas Hermanns |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-12-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1056823/full |
Similar Items
-
Treatment sequencing in metastatic castrate-resistant prostate cancer
by: Oliver Sartor, et al.
Published: (2014-06-01) -
Consensus on the Screening, Staging, Treatment, and Surveillance of Localized, Recurrent, and Metastatic Prostate Cancer: The First Global Prostate Cancer Consensus Conference for Developing Countries
by: Fernando Cotait Maluf, et al.
Published: (2021-12-01) -
The Value of Tumour Markers in the Detection of Relapse—Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study
by: Stefanie Fischer, et al.
Published: (2023-04-01) -
Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy
by: Aurelius Omlin, et al.
Published: (2014-02-01) -
Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses
by: Manolis Pratsinis, et al.
Published: (2022-06-01)